2.75

5.17% -0.15

Cellectar Biosciences Inc (CLRB)

Overview News Price History Financials Discussions Forecast Stock Split

Cellectar Biosciences Inc stock is traded at $2.75, with a volume of 35,440. It is down -5.17% in the last 24 hours and down -2.48% over the past month. Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.

Previous Close:

$2.90

Open:

$2.92

24h Volume:

35,440

Relative Volume:

0.51

Market Cap:

$11.70M

Revenue:

Net Income/Loss:

$-18.85M

P/E Ratio:

-0.4251

EPS:

-6.4686

Net Cash Flow:

$-29.75M

1W Performance:

-21.65%

1M Performance:

-2.48%

6M Performance:

-44.78%

1Y Performance:

+805.50%

1-Day Range:

$2.70

$2.95

1-Week Range:

$2.6601

$3.50

52-Week Range:

$0.23

$10.19

Cellectar Biosciences Inc Stock (CLRB) Company Profile

Name

Cellectar Biosciences Inc

Sector

Healthcare (1111)

Industry

Biotechnology (621)

Phone

(608) 441-8120

Address

100 CAMPUS DRIVE, FLORHAM PARK, NJ

Employee

Twitter

@CellectarBio

Next Earnings Date

2025-03-05

Latest SEC Filings

CLRB's Discussions on Twitter

Compare CLRB vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CLRB Cellectar Biosciences Inc	2.76	12.30M	0	-18.85M	-29.75M	-6.4686
VRTX Vertex Pharmaceuticals Inc	460.31	121.40B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	763.61	83.25B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	722.13	46.39B	4.16B	1.29B	734.26M	19.59
ALNY Alnylam Pharmaceuticals Inc	320.36	43.41B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	291.37	33.09B	5.36B	287.73M	924.18M	2.5229

Cellectar Biosciences Inc Stock (CLRB) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-05-24	Resumed	Ladenburg Thalmann	Buy
Jul-01-20	Initiated	Oppenheimer	Outperform
Jan-21-20	Resumed	ROTH Capital	Buy
Sep-13-19	Initiated	ROTH Capital	Buy
Dec-21-16	Initiated	Ladenburg Thalmann	Buy

Cellectar Biosciences Inc Stock (CLRB) Latest News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total
CARUSO JAMES V	Chief Executive Officer	Jul 02 '25	Buy	4.99	10,000	49,900	11,638
Longcor Jarrod	Chief Operating Officer	Jul 02 '25	Buy	4.99	10,000	49,900	12,768
Kolean Chad J	Chief Financial Officer	Jul 02 '25	Buy	4.99	5,000	24,950	6,418

Cellectar Biosciences Inc (CLRB)

Cellectar Biosciences Inc Stock (CLRB) Company Profile

Compare CLRB vs VRTX, REGN, ARGX, ALNY, ONC

Cellectar Biosciences Inc Stock (CLRB) Upgrades & Downgrades

Cellectar Biosciences Inc Stock (CLRB) Latest News

Cellectar Biosciences, Inc. (NASDAQ:CLRB) Q4 2025 Earnings Call Transcript - Insider Monkey

Cellectar (CLRB) Marks Significant Achievements in 2025 - GuruFocus

Cellectar Biosciences, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance

Earnings call transcript: Cellectar Biosciences Q4 2025 reveals strategic cost control - Investing.com

Cellectar (CLRB) Q4 2025 Earnings Call Transcript - The Globe and Mail

CLRB: Advanced late-stage pipeline, improved financials, and set up for major regulatory milestones in 2026 - TradingView

Cellectar Biosciences Reports Financial Results for Year Ended 2025 and Provides Corporate Updates - Investing News Network

CLRB: Advanced regulatory progress, reduced losses, and extended cash runway position for key 2026 milestones - TradingView

Cellectar Biosciences Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Earnings Summary: Cellectar Biosciences (CLRB) FY25 net loss narrows - AlphaStreet News

CLRB: Net loss narrowed as pipeline advanced toward key regulatory and clinical milestones - TradingView

Cellectar Biosciences 2025 10-K — Net loss $8.35 EPS; no revenue reported - TradingView

Cellectar (NASDAQ: CLRB) halves 2025 loss while pushing key cancer drugs - Stock Titan

Iopofosine progress at Cellectar (NASDAQ: CLRB) with pivotal WM data and FDA path - Stock Titan

Cellectar Biosciences, Inc. Advances Iopofosine I-131 Submission for Waldenström Macroglobulinemia and Initiates Phase 1b Study of CLR 125 in Triple Negative Breast Cancer - Quiver Quantitative

Cancer-drug firm gets FDA breakthrough tag, yet lost $21.8M in 2025 - Stock Titan

Insights into Cellectar Biosciences's Upcoming Earnings - Benzinga

Cellectar Biosciences Inc expected to post a loss of $2.02 a shareEarnings Preview - TradingView

Cellectar Biosciences (CLRB) to Release Earnings on Wednesday - Defense World

Rate Cut: Is Cellectar Biosciences Inc currently under institutional pressureJuly 2025 PreEarnings & AI Forecast Swing Trade Picks - baoquankhu1.vn

CLRB SEC FilingsCellectar Biosciences Inc 10-K, 10-Q, 8-K Forms - Stock Titan

Analyst Upgrade: Will Cellectar Biosciences Inc benefit from rising consumer demandMarket Sentiment Summary & Capital Protection Trade Alerts - baoquankhu1.vn

CLRB Earning Date, Earning Analysis and Earning Prediction - Intellectia AI

Nasdaq Moves: How cyclical is Cellectar Biosciences Incs revenue streamMarket Performance Recap & High Accuracy Trade Alerts - baoquankhu1.vn

Cellectar Biosciences to Report Full Year Financial Results and Host a Conference Call on Wednesday, March 4, 2026 - Investing News Network

CLRB Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan

Bull Bear: What drives Cellectar Biosciences Inc.’s stock priceQuarterly Profit Review & AI Forecasted Entry and Exit Points - mfd.ru

Gap Down: What are Cellectar Biosciences Incs growth leversJuly 2025 Action & Fast Entry Momentum Trade Alerts - baoquankhu1.vn

Biotech Exit: $26 Million Arcellx Sale Follows Tepid Stock Performance and Kelonia Competition - AOL.com

Cogent Biosciences Stock Up 346% as Fund Builds $29 Million Stake After November Phase 3 Breakthrough - AOL.com

Cellectar Biosciences Expands Global Intellectual Property Estate - Investing News Network

Cellectar Biosciences Expands Global Intellectual Property Portfolio Ahead of Iopofosine I 131 Marketing Approval for Waldenström Macroglobulinemia - Quiver Quantitative

Will Cellectar Biosciences Inc. benefit from rising consumer demandCEO Change & Comprehensive Market Scan Insights - mfd.ru

Analysis Recap: Whats the fair value of Cellectar Biosciences Inc stockQuarterly Portfolio Summary & Reliable Breakout Stock Forecasts - baoquankhu1.vn

Bleichroeder group discloses 4.61% CLRB stake in amended ownership filing - Stock Titan

Is Cellectar Biosciences Inc. stock risky to hold now2025 Top Gainers & Advanced Swing Trade Entry Alerts - mfd.ru

How cyclical is Cellectar Biosciences Inc.’s revenue streamEarnings Miss & Verified Technical Signals - mfd.ru

Is Cellectar Biosciences Inc. a top pick in the sector2025 Buyback Activity & Smart Investment Allocation Insights - mfd.ru

Will Cellectar Biosciences Inc. stock reach all time highs in 2025 - mfd.ru

Rosalind group discloses 5.5% Cellectar (CLRB) stake with conversion caps - Stock Titan

Can Cellectar Biosciences Inc weather a recession2025 Earnings Surprises & Risk Adjusted Swing Trade Ideas - baoquankhu1.vn

Can Cellectar Biosciences Inc. disrupt its industryQuarterly Growth Report & Real-Time Volume Spike Alerts - mfd.ru

Risk Report: Is BioLineRx Ltd Depositary Receipt a top pick in the sectorInsider Selling & Reliable Volume Spike Trade Alerts - baoquankhu1.vn

Weekly Trades: Is Cellectar Biosciences Inc a top pick in the sector - baoquankhu1.vn

What’s the fair value of Cellectar Biosciences Inc. stock - mfd.ru

Stock Analysis: What is the Moat Score of NAMIJuly 2025 EndofMonth & Free Expert Verified Stock Movement Alerts - baoquankhu1.vn

Can Cellectar Biosciences Inc disrupt its industryJuly 2025 Chart Watch & Growth Focused Stock Pick Reports - baoquankhu1.vn

What catalysts could drive Cellectar Biosciences Inc. stock higherMarket Insider Reports & Low Risk Trading Ideas - Bollywood Helpline

Is Cellectar Biosciences Inc currently under institutional pressure2025 Earnings Impact & High Return Trade Guides - baoquankhu1.vn

Fundamentals Check: How volatile is Cellectar Biosciences Inc stockWeekly Gains Report & Fast Gaining Stock Strategy Reports - baoquankhu1.vn

Ideas Watch: How cyclical is Cellectar Biosciences Incs revenue streamWeekly Stock Analysis & Accurate Intraday Trade Tips - baoquankhu1.vn

Cellectar Biosciences Inc Stock (CLRB) Financials Data

Revenue

Net Income

Cash Flow

EPS

Cellectar Biosciences Inc Stock (CLRB) Insider Trading

Similar to CLRB